# A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Source: https://onco.cc/trials/nct06522737/  
OnCo record `nct06522737` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Duvelisib, Gemcitabine and Bendamustine in non-Hodgkin lymphoma, run by SecuraBio, now recruiting.

## Summary

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype is a phase 3 interventional study registered as NCT06522737 by SecuraBio, with 124 participants planned, started 2025-05-19 and due to reach its primary completion in 2028-02. Interventions recorded: Duvelisib, Gemcitabine and Bendamustine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06522737
- Phase: 3
- Setting: A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
- Sponsor: SecuraBio
- Enrolled: 124

## Sources

- ClinicalTrials.gov NCT06522737: https://clinicaltrials.gov/study/NCT06522737

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Duvelisib](https://onco.cc/drugs/duvelisib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [SecuraBio](https://onco.cc/companies/securabio/)

---
JSON: https://onco.cc/api/v1/entities/nct06522737.json